Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections
2021-001003-32Phase 2Active
- Sponsor
- Antwerp University Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide in hepatitis B (HBV) (2 arms), sponsored by Antwerp University Hospital. Primary endpoint: Viral control at week 72 after treatment cessation. Started Jun 2021; status: active.
02
Drugs
entecavirtenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2021-001003-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001003-32.